Apalutamide with Androgen-Deprivation Therapy in Metastatic Castration-Sensitive Prostate Ca

A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020)

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020)

For More Information:

https://clinicaltrials.gov/study/NCT05884398?term=%09NCT05884398&rank=1